C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $777,930 | -59.8% | 418,242 | -40.5% | 0.00% | – |
| Q2 2023 | $1,933,476 | +10.1% | 703,082 | +25.8% | 0.00% | – |
| Q1 2023 | $1,755,430 | -24.2% | 559,054 | +42.4% | 0.00% | -100.0% |
| Q4 2022 | $2,316,341 | +81.7% | 392,600 | +170.0% | 0.00% | – |
| Q3 2022 | $1,275,000 | +332.2% | 145,387 | +271.3% | 0.00% | – |
| Q2 2022 | $295,000 | -91.5% | 39,151 | -72.6% | 0.00% | -100.0% |
| Q1 2022 | $3,467,000 | -40.3% | 142,929 | -20.8% | 0.00% | 0.0% |
| Q4 2021 | $5,811,000 | +174.2% | 180,456 | +280.4% | 0.00% | – |
| Q3 2021 | $2,119,000 | -57.7% | 47,435 | -64.2% | 0.00% | -100.0% |
| Q2 2021 | $5,013,000 | +569.3% | 132,478 | +554.2% | 0.00% | – |
| Q1 2021 | $749,000 | -78.2% | 20,251 | -80.5% | 0.00% | -100.0% |
| Q4 2020 | $3,441,000 | – | 103,873 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |